Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

To evaluate the use of hybrid closed-loop glucose control with faster-acting insulin aspart (Fiasp) in adults with type 1 diabetes (T1D).

Who Took Part

According to the abstract, 25 adults were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The adults were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

As a double-blind Insulin Aspart study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the adults took both Insulin Aspart and the comparison in turn, acting as their own control.

During both interventions the CamAPS FX closed-loop system incorporating the Cambridge model predictive control algorithm was used.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Aspart and Insulin Infusion Systems.

Author keywords: artificial pancreas, closed-loop insulin delivery, continuous glucose monitoring, faster insulin aspart, insulin pump therapy and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 25 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page, all human trials.